SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.-MedSci.cn

SAFETY AND RETENTION RATE AFTER SWITCHING FROM ETANERCEPT ORIGINATOR (ETN) TO ETANERCEPT BIOSIMILAR (SB4) IN INFLAMMATORY JOINT DISEASES: DATA FROM REAL LIFE.

Bruni, C; Gentileschi, S; Capassoni, M; Pacini, G; Bardelli, M; Baldi, C; Tofani, L; Cometi, L; Nacci, F; Bartoli, F; Fiori, G; Cantarini, L; Guiducci, S; Frediani, B; Matucci-Cerinic, M

ANNALS OF THE RHEUMATIC DISEASES, 2020; 79 (): 1435

科室
- - 订阅+
  - 更多科室
工具
服务